• UCLA Health
  • myUCLAhealth
  • School of Medicine
Institute of Urologic Oncology

UCLA Institute of Urologic Oncology

Institute of Urologic Oncology
  • About Us
    • Director's Welcome
    • Board of Directors
    • IUO in the News
    • Why Choose the UCLA IUO
    • Support the IUO
    • Contact Us
    • The Wasserman Building
    • Maps and Directions
    • IUO Membership Information
    • Administrative & Research Staff
    • Positions Available
  • Clinical Programs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Integrated Cancer Program
    • Cancer Genetic Risk Assessment Program
    • Second Opinion for Cancer
  • Research Programs
    • Clinical Trials
    • Faculty Labs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • PSMA Risk Calculator
    • SPORE In Prostate Cancer
    • External Funding Opportunities
    • Webinars / Videos
  • Clinical Trials
    • What Is a Clinical Trial?
    • Who Should Consider Clinical Trials & Why
    • Bladder Cancer Clinical Trials
    • Kidney Cancer Clinical Trials
    • Prostate Cancer Clinical Trials
    • Clinical Research Team
    • IUO Membership Study Information
  • For Patients
    • Contact Us
    • Clinical Updates
    • Health Plans and Financial Matters
    • Maps and Directions
    • myUCLAhealth
    • Patient Testimonials
    • Preparing for Surgery
    • Webinars / Videos
  • Fellowship
    • Current Fellows
    • Former Fellows
    • Fellow Testimonials
    • UCLA Health Aerial Tour
  • For Healthcare Professionals
    • How to Refer a Patient
    • Lectures & Conferences
    • CTSI Distinguished Speaker Seminar Series
    • DGSOM Research Seminars
    • DGSOM Events
    • JCCC Seminars
    • SPORE Lectures
    • External Funding Opportunities
  • Expert Team
    • Board of Directors
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Institute of Urologic Oncology

Clinical Trials

Clinical Trials

Clinical Trials

  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  1. Home
  2. Institute of Urologic Oncology
  3. Clinical Trials
  4. Testing the Addition of the Drug Nivolumab Before and after Surgery for Renal Cell Cancer

Testing the Addition of the Drug Nivolumab Before and after Surgery for Renal Cell Cancer

Share this

Testing the Addition of the Drug Nivolumab Before and after Surgery for Renal Cell Cancer

Lay Title: Testing the Addition of the Drug Nivolumab Before and after Surgery for Renal Cell Cancer

Technical Title: PROSPER RCC:  EA8143: A Phase 3 RandOmizedStudy Comparing PERioperative Nivolumab vs. Observation in Patients with Localized RenalCell Carcinoma Undergoing Nephrectomy

Disease Type:Patients with renal cell carcinoma (a type of kidney cancer) who are planned to have a nephrectomy (surgical removal of the kidney)

Basic information: The purpose of this study is to compare the effects of a drug called nivolumab (also known as OPDIVO®), before and after the kidney cancer surgery to using the usual approach of surgically removing the kidney cancer followed by standard post-operative follow-up and monitoring. Nivolumab is a drug that may help stimulate your immune system to attack any cancer cells that may remain after surgery. The addition of nivolumabto the usual surgery could prevent your cancer from returning but it could also cause side effects.

Nivolumab is already FDA-approved for patients who have kidney cancer that has spread outside of the kidney to other organs or lymph nodes. The use of nivolumab in this study is investigational (not approved by the FDA) for your early stage of cancer where we do not know for sure if the disease has spread outside of the kidney. 

If you participate in the study, you will be randomized to one of two groups: (1) receive nivolumab before and after your scheduled kidney cancer surgery, or (2) observation after kidney cancer surgery (which is the routine approach taken for this early stage of kidney cancer).

Research Procedures (not a complete list):
If you are randomized to receive nivolumab, you will receive 2 doses of nivolumab – once every two weeks – before surgery. Starting 4 weeks after surgery, you will receive 12 doses of nivolumab over 9 months. The first 6 doses will be given every 2 weeks, and the last 6 doses will be given every 4 weeks. During study visits, you will undergo a physical exam and have blood drawn for safety and research tests.

If you are randomized to receive usual care, you will undergo routine monitoring after surgery.

Eligibility Criteria (Not a complete list):
Inclusion Criteria:

  • New diagnosis of renal cell carcinoma (RCC)
  • Planned kidney cancer surgery (radical or partial nephrectomy)

Exclusion Criteria:

  • No metastases
  • No prior treatment for kidney cancer (such as chemotherapy, radiation therapy, etc.)
  • No diagnosis of hepatitis B, hepatitis C, or HIV

For More Detailed Information, Contact:

  • Brian Shuch, MD, Principal Investigator, Associate Professor of Urology 
  • Rosleen Mala, Study Coordinator, (310) 794-3879
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest